TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06006572

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive
Description: wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive
Description: wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive
Study: NCT05913102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PDLLA
Description: Administer PDLLA/saline every 2 weeks for 2.5 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDLLA
Description: Administer PDLLA/saline every 2 weeks for 2.5 months
Study: NCT06099106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEPIOLA System
Description: Implantation of the SEPIOLA device into the left atrial appendage.
Study: NCT04893018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efineptakin alfa
Description: Given IM
Study: NCT06227689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccine chatbot that offering HPV vaccine-related information
Description: The intervention group will be invited to use the HPV vaccine chatbot online through WeChat or any web browsers, where they can ask any questions related to the HPV vaccine and get previously validated answers from the chatbot immediately. All the answers will be drawn from a database, whose content were obtained from official websites of Chinese government, HPV vaccine enterprises, and International organizations like WHO, and had been validated by experts. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention.
Study: NCT06335589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EBP-Massed
Description: CPT or PE will be delivered in a massed format (e.g., sessions at least 3 days per week)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EBP-TAU
Description: CPT or PE will be delivered treatment as usual, which is typically once per week.
Study: NCT05883566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experimental
Description: During the procedure, the chairside assistant can capture video recordings of the child's behavior and facial expressions. These videos can be later reviewed by a trained observer who can evaluate the child's pain experience
Study: NCT05564364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recumbent Bike
Description: The first group will exercise with a recumbent bike for 20 minutes, 3 sessions/week for 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upright Bike
Description: The first group will exercise with a upright bike for 20 minutes, 3 sessions/week for 6 weeks.
Study: NCT05237713

Intervention type: DRUG
Group type: OTHER
Intervention: Canakinumab Injection
Description: Administration for a duration of 6 months for all patients and in case of response further treatment for up to three years
Study: NCT05528601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: use of Endo App®
Description: use of Endo App® smartphone application containing endometriosis relevant exercises and educational material
Study: NCT02985671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orphenadrine, acetaminophen, caffeine and diclofenac sodium
Description: orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg tablet
Study: NCT05020964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab and Pyrotinib
Description: Trastuzumab: 3-week dosing regimen, The initial load dose was 8 mg/kg. Pyrotinib: 400 mg orally once daily, take it continuously, every 21 days as a cycle.~Use until intolerable toxicity or disease progression occurs.
Study: NCT06175351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW1911
Description: Participants will receive IV 9MW1911 every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW1911
Description: Participants will receive IV 9MW1911 every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV placebo every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV placebo every 4 weeks.
Study: NCT02677636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSRD-100
Description: MSRD-100 is a topical gel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle is a topical gel without the active ingredients in MSRD-100
Study: NCT05257148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofenopril 30 mg
Description: Film-Coated tablets administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol 5 mg
Description: Tablet administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofenopril 30 mg + Nebivolol 5 mg
Description: Both Film coated tablets of Zofenopril 30 mg and Nebivolol 5 mg Tablets will be taken in the morning (from 6 am to 10 am) with no restriction on food intake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofenopril 30 mg + Nebivolol 5 mg
Description: Both Film coated tablets of Zofenopril 30 mg and Nebivolol 5 mg Tablets will be taken in the morning (from 6 am to 10 am) with no restriction on food intake
Study: NCT02985671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium 50 MG
Description: Voltaren (diclofenac sodium 50mg) tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for experimental drug)
Description: tablet without active substances, manufactured to mimic experimental product tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Voltaren)
Description: tablet without active substances, manufactured to mimic Voltaren 50mg tablet
Study: NCT05957744

Intervention type: PROCEDURE
Intervention: Colorectal surgery
Description: Right hemicolectomy, left colectomy, total colectomy, anterior resection

Intervention type: PROCEDURE
Intervention: Colorectal surgery
Description: Right hemicolectomy, left colectomy, total colectomy, anterior resection
Study: NCT05578183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: theta burst stimulation
Description: expect for the TBS, all patients get cognitive training alike on a training system in medical center.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: theta burst stimulation
Description: expect for the TBS, all patients get cognitive training alike on a training system in medical center.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: expect for the TBS, all patients get cognitive training alike on a training system in medical center.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: expect for the TBS, all patients get cognitive training alike on a training system in medical center.
Study: NCT05650840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Charcoal based whitening toothpaste (signal charcoal white& Detox toothpaste Unilever Mashreq - Egypt
Description: The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded.~Intervention drug : whitening toothpaste charcoal based whitening toothpaste compared to calcium carbonate and perlite whitening toothpaste~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush (Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate /perlite containing whitening toothpaste (signal whitening moonlight toothpaste Unilever Mashreq - Egypt).
Description: The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using calcium carbonate /perlite containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded. The main operator will perform the tooth brushing procedures for all the patients himself twice daily.~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush(Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination Device used is atomic force microscopy to determine enamel abrasion after brushing
Study: NCT06380842

Intervention type: OTHER
Intervention: Necrotizing Pancreatitis patients' organ dysfunction progression
Description: Study the dynamic nature of organ dysfunction
Study: NCT04594473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Oncology Rehabilitation and Exercise (CORE) Program
Description: \[see arm/group descriptions\]
Study: NCT06021691

Intervention type: BEHAVIORAL
Intervention: Acquired nurturing environment
Description: Superimposed effects of intrauterine high-sugar environment exposure and postnatal nurturing environment exposure

Intervention type: BEHAVIORAL
Intervention: Acquired nurturing environment
Description: Superimposed effects of intrauterine high-sugar environment exposure and postnatal nurturing environment exposure
Study: NCT05864508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: intranasal oxytocin treatment once a day during 6 weeks
Study: NCT05333666

Intervention type: OTHER
Intervention: Data collection
Description: This investigation aims to collect and analyze the data from a cohort. During the cohort development, all participants received venous puncturing for NOAC concentration measurement. However, the standard treatment protocol was not changed after study enrollment. In this retrospective cohort study, we only collect data from the cohort without further intervention to the participants.
Study: NCT04666181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task training
Description: See descriptions under arm description. The dual-task training will occur across a total of 5 consecutive workday visits.
Study: NCT05178511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Ensaritinib was taken orally once 225mg, on an empty stomach or with food, until the patient developed disease progression, developed unacceptable toxicity, the investigator or subject decided to drop out, lost follow-up, initiated other antitumor therapy, or died
Study: NCT06085040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary weight loss
Description: 12-months multidisciplinary behavioral intervention combining physical activity (3 times 60 minutes per week), nutritional guidance (balanced meals) and psychological support (60 minutes per week)
Study: NCT04961125

Intervention type: GENETIC
Intervention: germline variants
Description: Variants of 139 genes associated with different hereditary cancers and polyposis were screened by next-generation sequencing.
Study: NCT05871008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment tool IA3-CP with SDoH
Description: Each patient randomly assigned to IA3-CP with SDoH study arm will complete a pre-visit assessment tool including SDoH. Feedback is provided to provider and patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment tool IA3-CP without SDoH
Description: Each patient randomly assigned to IA3-CP only study arm will complete a pre-visit assessment tool excluding SDoH. Feedback is provided to provider and patient.
Study: NCT05248776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL207280
Description: IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL207280
Description: IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL207280
Description: IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL207280
Description: IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet.
Study: NCT06492421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
Description: This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
Description: This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
Description: This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times.
Study: NCT05040867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Description: The physical exercise programme will last 16 weeks where participants will do three weekly sessions of 60 minutes, approximately. In these training sessions, cardiovascular and strength components will be worked out, planned from moderate to high intensity in the TEG and unique high intensity in the HRVG. The training programme will be divided into three mesocycles from neuromuscular adaptation to reach, in last period, the highest loads and cardiovascular levels. Each session will include a warm-up, a main part and a cool-down with stretching and mobility exercises.~The difference between the interventions of the HRVG and TEG will be in the planning of the intensity of the cardiovascular exercises and the weight to be lifted in the strength exercises. The first session of both programmes will have the same intensity but depending on how the heart rate variability of the HRVG patients reacts to, the weight and the intensity will be individualised each day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Description: The physical exercise programme will last 16 weeks where participants will do three weekly sessions of 60 minutes, approximately. In these training sessions, cardiovascular and strength components will be worked out, planned from moderate to high intensity in the TEG and unique high intensity in the HRVG. The training programme will be divided into three mesocycles from neuromuscular adaptation to reach, in last period, the highest loads and cardiovascular levels. Each session will include a warm-up, a main part and a cool-down with stretching and mobility exercises.~The difference between the interventions of the HRVG and TEG will be in the planning of the intensity of the cardiovascular exercises and the weight to be lifted in the strength exercises. The first session of both programmes will have the same intensity but depending on how the heart rate variability of the HRVG patients reacts to, the weight and the intensity will be individualised each day.
Study: NCT04781868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplement
Description: Multi-nutrient supplement containing a combination of vitamins, minerals and antioxidants

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04247191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P-Chat
Description: The P-Chat is a brief individually delivered intervention based on the principles of Motivational Interviewing (MI) and focuses on increasing parents' motivation to reduce permissiveness toward underage alcohol use while reducing defensiveness and barriers to implementing these rules with their teen.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PBI
Description: The PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of the two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third, is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P-Chat+
Description: The P-Chat+ is a combination of the P-Chat and PBI described above. Parents in this arm of the study will receive both interventions.
Study: NCT05123404

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: multi parametric MRI
Description: In our study we aim to evaluate role of Multiparametric MRI in differentiation between invasive and non-invasive bladder cancer and accuracy of vesical imaging reporting and data system (VI-RADS) score.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transurethral resection of bladder tumor
Description: detection of degree of invasion to test accuracy of ViRADS score
Study: NCT06499142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parakeet:The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample.
Description: The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample. The Parakeet is a point of care test completely controlled by the surgeon and operating team. It uses the scientific principle of Lateral Flow of antibody-antigen-conjugate complexes being arrested in a Test Line.
Study: NCT05537974

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endotracheal aspiration
Description: Clearance of endotracheal secretions via a catheter.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endotracheal aspiration
Description: Clearance of endotracheal secretions via a catheter.
Study: NCT06370481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Routine care administered via telemedicine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care, as received in HIV clinic settings
Study: NCT06205329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPV01 Dose 1-4
Description: WPV01 Dose 1-4 or Placebo on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPV01 Dose 5-8 and Ritonavir
Description: WPV01 Dose 5-8 and Ritonavir or Placebo on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPV01 Dose 9-12
Description: WPV01 Dose 9-12 or Placebo from day 1 to day 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPV01 Dose 13-15 and Ritonavir
Description: WPV01 Dose 13-15 and Ritonavir or Placebo from day 1 to day 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPV01 Dose 16
Description: Cohort 1:WPV01 Dose 16 or Placebo (with high fat meal) Cohort 2:WPV01 Dose 16 or Placebo (fasted)
Study: NCT04969549

Intervention type: OTHER
Group type: OTHER
Intervention: Theta burst stimulation
Description: It consists of 20 sessions of iTBS over the dlPFC.